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Abstract
Background: Bisphosphonates can reduce fracture risk in patients with osteoporosis, but many
at-risk patients do not start or adhere to these medications. The aims of this study are to: (1)
preliminarily evaluate the effect of an individualized 10-year osteoporotic fracture risk calculator
and decision aid (OSTEOPOROSIS CHOICE) for postmenopausal women at risk for osteoporotic
fractures; and (2) assess the feasibility and validity (i.e., absence of contamination) of patient-level
randomization (vs. cluster randomization) in pilot trials of decision aid efficacy.
Methods/Design:  This is a protocol for a parallel, 2-arm, randomized trial to compare an
intervention group receiving OSTEOPOROSIS CHOICE to a control group receiving usual primary care.
Postmenopausal women with bone mineral density T-scores of <-1.0, not receiving bisphosphonate
therapy, and receiving care at participating primary care practices in and around Rochester,
Minnesota, USA will be eligible to participate in the trial. We will measure the effect of
OSTEOPOROSIS CHOICE on five outcomes: (a) patient knowledge regarding osteoporosis risk factors
and treatment; (b) quality of the decision-making process for both the patient and clinician; (c)
patient and clinician acceptability and satisfaction with the decision aid; (d) rate of bisphosphonate
use and adherence, and (e) trial processes (e.g., ability to recruit participants, collect patient
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outcomes). To capture these outcomes, we will use patient and clinician surveys following each visit
and video recordings of the clinical encounters. These video recordings will also allow us to
determine the extent to which clinicians previously exposed to the decision aid were able to
recreate elements of the decision aid with control patients (i.e., contamination). Pharmacy
prescription profiles and follow-up phone interviews will assess medication start and adherence at
6 months.
Discussion: This pilot trial will provide evidence of feasibility, validity of patient randomization,
and preliminary efficacy of a novel approach -- decision aids -- to improving medication adherence
for postmenopausal women at risk of osteoporotic fractures. The results will inform the design of
a larger trial that could provide more precise estimates of the efficacy of the decision aid.
Trial registration: Clinical Trials.gov Identifier: NCT00578981
Background
The societal burden associated with osteoporotic fractures
is already great[1], but is expected to increase further with
aging of the population [2]. Randomized trials have con-
clusively shown that use of bisphosphonate therapy in
postmenopausal women can reduce their risk of oste-
oporotic fractures. Postmarketing studies have established
a favorable balance of benefit over harms [3]. Limited
start and adherence to bisphosphonates in at-risk
patients, however, reduces this beneficial impact [4-7].
When bisphosphonates are prescribed, about 50% of
patients discontinue therapy within one year of its pre-
scription [8,9]. Given current estimates of the prevelance
of at-risk people -- the National Osteoporosis Foundation
estimates that 44 million people in the United States age
50 years or over have either osteoporosis or osteopenia
[10] -- the potential morbidity, mortality and expense
associated with bisphosphonate nonadherence is signifi-
cant.
Poor adherence appears related, in part, to undisclosed
and unexplored patient values and preferences [11,12], as
well as gaps in patient understanding of the efficacy and
safety of pharmacologic treatment [13]. One way to facil-
itate patient understanding and to elicit patient prefer-
ences is to use decision aids in consultations. Decision
aids are tools that help patients participate in choosing
among management options by providing them with
information about the relevant features of the available
choices. A systematic review of 55 randomized trials of
decision aids vs. usual care, pamphlets, or education
revealed that, overall, decision aids are effective at
improving knowledge acquisition and reducing so-called
decisional conflict (i.e., uncertainty about the choice,
ignorance about the pros and cons of each option, pres-
sure to make a particular choice, and effectiveness of the
decision) [14]; their effect on medication adherence
remains largely unknown.
To our knowledge, our group has produced the only ran-
domized trial evidence supporting improvements in
adherence to preventive medications, using a decision aid
about statins in patients with type 2 diabetes [15]. In this
case, clinicians and patients found the tool, Statin Choice,
acceptable; and, compared with no intervention, patients
receiving the decision aid had more knowledge about and
more accurate expectations of potential benefits and
harms of statin use. They also reported significant reduc-
tions in decisional conflict and showed a 3-fold increase
in the odds of self-reported adherence to statins at 3
months.
The timing for OSTEOPOROSIS CHOICE has coincided with a
paradigm shift in the management of osteoporosis [10].
The prior standard approach relied most heavily on bone
mineral density (BMD) results as measured with dual-
energy X-ray absorptiometry (DXA) to inform practice
guidelines and treatment decisions [16,17]. While BMD
T-scores can identify high risk patients, they are both
insensitive and nonspecific [18] since they do not address
other pertinent factors related to risk of fracture [19].
Moreover, the actual probability of experiencing an oste-
oporotic fracture with any given T-score is not immedi-
ately evident or available [20]. With the arrival of FRAX,
the World Health Organization's calculator of 10-year
osteoporotic fracture risk [21], treatment recommenda-
tions can now be commensurate with the probability of a
hip fracture or any major osteoporotic fracture (hip,
spine, distal forearm, humerus). FRAX risk estimates are
based on population-based cohort studies. These studies
generated models that incorporate a patient's BMD at the
femoral neck, when available, and clinical risk factors.
These factors include age, sex, ethnicity, body mass index,
personal and parental history of prior osteoporotic frac-
ture, long term use of oral glucocorticoids, rheumatoid
arthritis or other secondary causes of osteoporosis (e.g.
type 1 diabetes, premature menopause, chronic malab-Trials 2009, 10:113 http://www.trialsjournal.com/content/10/1/113
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sorption, hyperthyroidism, hypogonadism), and current
alcohol and tobacco use [19]. Current osteoporosis prac-
tice guidelines incorporate the use of FRAX [10], but opti-
mal use of this tool is still evolving [20].
At the onset of this project, the best available decision aid
for osteoporosis treatment was 35 pages long [22], did not
incorporate absolute fracture risk estimates, and its effi-
cacy remained unexplored. In contrast, OSTEOPOROSIS
CHOICE:
• is a one page, paper-based decision aid;
￿ incorporates a specific patient's 10-year risk of an oste-
oporotic fracture estimated using the FRAX online calcula-
tor http://www.shef.ac.uk/FRAX/; and
￿ is designed for use between patients and their clinicians.
The aim of this study is to evaluate the effect of an individ-
ualized fracture risk calculator and decision aid for post-
menopausal women at risk of osteoporotic fractures,
OSTEOPOROSIS CHOICE, on knowledge transfer, the quality
of the decision making process, and on patient adherence
to medications. Given our choice of study design, i.e., ran-
domization at the patient level, we also will seek to evalu-
ate the potential for contamination and poor fidelity in
the use of the decision aid in this setting. Here we present
the protocol we are using to conduct this trial.
Methods
Design
To evaluate the decision aid, we propose to conduct a
patient-level multicenter randomized trial. The Mayo
Clinic Institutional Review Board approved all study pro-
cedures.
Setting
Patients and primary care clinicians for this trial are to be
recruited at 10 practice sites affiliated with the Mayo
Clinic, all located in Southeastern Minnesota within a 60-
mile radius of Rochester, Minnesota, USA.
Participants
Inclusion criteria
Eligible clinicians include physicians, physician assistants
and nurse practitioners at participating sites. Eligible
patients include postmenopausal women, age 50 and over
who have BMD levels consistent with a diagnosis of low
bone mass (osteopenia) or osteoporosis, who are not tak-
ing bisphosphonates or other prescription osteoporosis
medications to treat low bone mass (other than vitamin D
and calcium), whom their clinicians find eligible for
bisphosphonate therapy and have a follow-up appoint-
ment with their clinician, and who are available for a tel-
ephone follow-up 6 months after randomization.
Exclusion criteria
The trial will exclude women who cannot read English or
have, in their clinicians' judgment, major learning barriers
such as visual or hearing impairment or dementia that
would compromise their ability to give written informed
consent (or use the decision aid).
Participant recruitment
We will identify eligible women from DXA lists and from
participating clinicians' appointment calendars. If there
were no pre-scheduled follow-up appointments after the
BMD evaluation, we will request participating clinicians
schedule such an appointment to discuss abnormal BMD
results with the patient during an office visit, not via a tel-
ephone conversation. The study coordinator will inform
patients about the trial, confirm their eligibility, and
obtain written informed consent in a private room at the
clinic site. Patients will be offered 15 dollars in compen-
sation for time spent completing study procedures.
Interventions
Decision aid
The OSTEOPOROSIS CHOICE decision aid tool was developed
through an iterative process and with extensive field-test-
ing involving patients, clinicians, designers, and research-
ers [23,24]. This one-page decision aid provides the
patient's individualized 10-year risk estimate of having a
major osteoporotic fracture (clinical spine, forearm, hip
or shoulder fracture). The risk is calculated using data
from the patient's medical record (completed by direct
query to patient or clinician as needed) and entering it
into the online FRAX tool as implemented during the
course of the study.
We developed three decision aids that describe the pros
and cons of treatment, one for each of three categories of
estimated 10-year risks of fracture: <10%, 10-30%, and
>30%. At the time we designed the decision aids, there
were no guidelines to orient therapeutic decisions based
on fracture risk. Thus, the design team, in conjunction
with patients and clinicians, arbitrarily chose these thresh-
olds. The decision aid also shows the patient-specific
absolute reduction of fracture risk with alendronate,
assuming a treatment-related reduction in overall oste-
oporotic fracture risk of 40% [25], and the potential
downsides of taking bisphosphonates.
To estimate the gastrointestinal side effects of oral
bisphosphonates we reviewed the FDA-approved package
insert, reports of pivotal clinical trials, and observational
studies [3]. Evidence of the association between bisphos-
phonate use and osteonecrosis of the jaw was also evolv-
ing while we were designing the tool [26]. The estimate
presented was derived from available reviews of weak evi-
dence and expert judgment from specialist clinicians on
our research team [27]. Finally, the decision aid alsoTrials 2009, 10:113 http://www.trialsjournal.com/content/10/1/113
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prompted further discussion of these issues with the ques-
tion "What would you like to do? (Figure 1).
In the intervention arm, a study coordinator will review
with the clinician the patient's tailored OSTEOPOROSIS
CHOICE decision aid tool immediately prior to the clini-
cian's visit with that patient. The clinician and the patient
will then review the decision aid together in the context of
their clinical encounter. This procedure, which is similar
to one used in our prior decision aid trial in primary care
[28], has the advantages of being time-sensitive and incor-
porates as-needed just-in-time training in the use of the
tool. We have found that clinicians delivering decision
aids during the visit yield somewhat superior results (e.g.
significantly improved knowledge transfer) to researchers
delivering the tool prior to the visit [29].
Usual care
In the usual care arm, the clinician will discuss the
patient's BMD test results and options for treatment in
that clinician's usual fashion, i.e., with no other research-
related intervention. The patient will receive the National
Osteoporosis Foundation booklet, "Boning Up On Oste-
oporosis: A Guide To Prevention and Treatment."
Randomization
A computer-generated allocation sequence will rand-
omize patients 1:1 in a concealed fashion to control
(usual care + booklet) or intervention (OSTEOPOROSIS
CHOICE decision aid). The study coordinator will complete
the following steps:
￿ assess the eligibility of the patient, obtain the patient's
written informed consent and enroll the patient;
￿ access a secure study website, input patient identifiers to
document patient eligibility;
￿ obtain from the website interface the arm of the study to
which the patient is allocated;
￿ when the website is not available, the coordinator will
contact the study statistician and a similar procedure will
be used to provide concealed random allocation.
After randomization, only data analysts will remain blind
to allocation. If a patient were suspected of having incor-
rectly enrolled, e.g., the patient is found to be ineligible
after enrollment and randomization, the study coordina-
tor will present the case to the study principal investigator
(V.M.M.) for consideration. Following existing recom-
mendations [30], the principal investigator will decide on
exclusion while unaware of any consequences of enroll-
ment, including the patient's allocation or outcomes.
The following issues were considered in our choice[15] to
randomize clinics, clinicians, or patients:
￿ Randomize by clinics - This approach would enable us to
train everyone in the intervention (and control) clinics to
use (or not) the decision aid. Disadvantages included the
small number of available clinics, difficulty in balancing
the number of participating clinicians and patients across
sites, and limited ability to avoid selection bias or imple-
ment allocation concealment.
￿ Randomize by clinicians - This approach would enable cli-
nicians to develop skills for using the decision aid, and
resolve any confusion related to when each clinician
Osteoporosis Choice decision aid for a patient with a 10-year fracture risk of 20% Figure 1
Osteoporosis Choice decision aid for a patient with a 10-year fracture risk of 20%.Trials 2009, 10:113 http://www.trialsjournal.com/content/10/1/113
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should use or not use the decision aid. Unfortunately, in
our judgment, these advantages did not outweigh the ina-
bility to implement allocation concealment, the residual
potential for selection bias, and the potential for a large
imbalance of numbers of patients per clinician that could
emerge [15]. Because of the relatively small number of
participating clinicians, clinician charisma or communi-
cation skills could confound the results of the effect of the
decision aid. Finally, there could be a potential risk of
recruitment and randomization of clinicians with few or
null eligible or enrolled patients during the trial.
￿ Randomize by patients - This approach would enable allo-
cation concealment and avoid selection bias. However, it
opens the study to the potential for contamination at the
clinician level; it is difficult logistically to determine when
a clinician will use the decision aid or not (and therefore
expedite recruitment in a busy practice setting); and it
slows the learning curve that may exist when clinicians
adapt to using the decision aid in practice.
Because the design was simple and we placed a high value
in avoiding bias, we implemented this third approach.
The main disadvantage of patient randomization is clini-
cian contamination. Contamination in this case refers to
a clinician who, having used the decision aid with a prior
patient, is able to recreate elements of the decision aid
with a subsequent patient allocated to receive usual care.
We use the term 'recreate' given that clinicians will not
have access to the decision aid when seeing patients not
allocated to the intervention arm. We recognize that clini-
cians could produce these elements by drawing from their
own knowledge base, i.e., not true contamination, so to
this extent this assessment may overestimate the rate of
contamination.
Since we did not find a published approach to determine
the extent to which this design could introduce contami-
nation, we developed a "contamination checklist" with
which to judge how clinicians will present information
about osteoporosis risk and treatment effect of bisphos-
phonates in video recordings of the clinical encounters
(see below). The tool checks for clinicians' use of 12 key
elements of the decision aid (Additional File 1) when see-
ing a control patient. A score of 12 in a control visit with
a clinician who has previously used the decision aid
would indicate maximum contamination (note that a
score of 12 in an intervention patient would indicate max-
imum fidelity in delivering the decision aid). Given the
small sample size and number of clinicians likely to enroll
more than one patient, only a few instances of potential
contamination (i.e., control patients visit with a clinician
who has had a decision aid visit previously) are likely to
take place. Therefore, our analyses will be limited to
descriptions of the distribution of overall scores and the
frequency of each item.
Outcomes and data collection
In this pilot trial, we will note the success and viability of
the trial processes, including the proportion of eligible
patients and clinicians we are able to recruit and our abil-
ity to collect and analyze all outcomes in all randomized
patients, i.e., to adhere to the intention to treat principle.
To assess efficacy, we will measure the effect of OSTE-
OPOROSIS CHOICE on the following outcomes: (a) patient
knowledge about osteoporosis risk factors and treatment;
(b) quality of the decision-making process for patient and
clinician; (c) patient and clinician acceptability and satis-
faction with the decision aid; and (d) rate of bisphospho-
nate use and adherence in at-risk women. We will survey
patients and clinicians after each visit (the complete set of
questions is in the appendix) and video record the clinical
encounters to capture these outcomes. Pharmacy prescrip-
tion profiles and follow-up telephone interviews will
assess medication start and adherence at 6 months.
The patient questionnaire includes:
￿ Items about education level, annual income and health
status for descriptive purposes.
￿ 15 items to assess patient knowledge, 13 of which refer
to osteoporosis in general and the benefits and downsides
of taking a bisphosphonate (9 questions about informa-
tion on the decision aid, 4 questions not informed by con-
tent on the decision aid), as well as two questions about
patient's personalized fracture risk and estimated risk
reduction with bisphosphonates. These items were fash-
ioned after similar items showed construct validity and
responsiveness to the intervention in previous decision
aid trials [14,15,28].
￿ 5 items using a 7-point Likert-type scale to assess the
patient's perceptions of the amount, clarity and helpful-
ness of information, their desire to receive information
about other medical treatment choices in the same way
this information was delivered, and whether they would
recommend the way they received information from their
clinician during this visit to other patients. We have used
these same items in our previous trials [15,28].
￿ 10 items from the Trust in Physician scale [31] and
￿ 16 items from the Decisional Conflict Scale [32] -- the
most commonly used outcome measure in clinical trials
of decision aids, which assesses the extent to which the
decision was informed, consistent with values, free of
pressure, and effective.
￿ Additional questions (see appendix) inquire about the
treatment decision made during the visit and patient sat-Trials 2009, 10:113 http://www.trialsjournal.com/content/10/1/113
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isfaction with the degree of participation in the decision-
making process.
The clinicians' survey, to be completed after each study
visit, includes questions regarding which decision the
patient made, the clinician's confidence in the patient's
understanding of the information offered, and the clini-
cian's prediction of patient action (start and adherence to
bisphophonates at 6 months).
To evaluate the quality of decision-making, we will use
the OPTION scale [33] on the video recordings. This scale
allows an observer to quantify the extent to which clini-
cians are able to involve patients in the decision-making
process. We have used the OPTION scale on video-
recorded encounters with adequate reliability in previous
studies [28,34]. Video recordings also provide informa-
tion about encounter duration (using the video time
stamps), fidelity of use of the tool, and difficulties and
successes experienced while using the decision aid, and
are the source of data for the contamination checklist
described above.
We will use two methods to assess patient adherence to
bisphophonates at six months. We will contact patients by
telephone and measure patient self-reported adherence
using the Haynes' single item adherence question ("Have
you missed any of your pills in the last week?") a measure
associated with a 96% specificity and 75% accuracy vs. a
pill count standard [35,36]. We will also obtain patients'
pharmacy records in order to objectively determine med-
ications filled since the study visit. Using this information,
we will consider a gap (time without medication) of
longer than 90 days as bisphosphonate discontinuation.
We will assess adherence to bisphosphonates by assessing
the proportion of days covered during the 180 days after
the visit, taking into account potential overlap in supply
that may result when a refill comes before the estimated
completion of the previous fill. We will define persistence
as the number of days from the first prescription fill to the
last fill in the 180 days after the visit. In this case, we will
take into account overlapping supply and the number of
days supplied at the last fill, truncating at 180 days after
the visit [37,38]. In addition to these continous measures,
we will assess and compare the proportion of patients
who exhibited ≥ 80% adherence to bisphosphonates in
both groups.
Statistical considerations
We have funding and plan to enroll and randomize 100
patients. While this number of patients is insufficient to
reach a definitive answer about the efficacy of the decision
aid and its effect on medication adherence, it is sufficient
to ascertain the following differences:
￿ for knowledge gains, assuming that patients in the con-
trol group will be able, on average, to answer 4 of the 9
specific knowledge questions correctly, we will have 92%
power to detect a ≥42.5% increase in mean knowledge (to
a mean of 5.6 questions answered correctly) in the inter-
vention group, assuming equal variances between the two
arms and alpha = 0.05;
￿ for adherence, estimating that the 6 month adherence
rate is 65% (null hypothesis), we will be powered (80%)
to detect a difference (alpha = 0.05) in adherence rates of
35% (88% alternative hypothesis). To our knowledge,
there is no policy- or patient-important minimum differ-
ence in adherence rates identified in the literature to oth-
erwise guide the choice of a threshold.
The distribution of study variables will be described
(using frequencies for categorical variables and measures
of central tendency for continous variables) and com-
pared using relative (relative risk) or absolute (mean dif-
ferences) measures of association and their 95%
confidence intervals. Because we expect a very low patient-
to-clinician ratio, we do not anticipate having to use gen-
eralized estimating equations to adjust for clustering by
clinician. To test hypotheses of association, we will use
Wilcoxon rank-sum tests to compare medians, and Chi-
square or Fisher's Exact tests to compare frequencies. All
analyses are based on two-sided tests at significance level
0.05. Consistent with the intention to treat principle [39],
all efforts will be placed on avoiding missing data and all
patients will be analyzed in the arm to which they were
randomized; participants with missing data will not be
part of the analyses requiring the missing data. All analy-
ses will be conducted using SAS (SAS Institute, Cary, NC).
Discussion
We have presented the design of a trial to evaluate the
effect of a decision aid for bisphosphonate treatment in
postmenopausal women receiving primary care (OSTE-
OPOROSIS CHOICE). While this is a feasibility trial for a new
decision aid, we also seek to determine if the decision aid
can transfer knowledge, and if so, can it improve patient
involvement in making decisions about their care, and
whether such an improvement will have a discernible
effect on adherence. We also discuss the pros and cons of
patient randomization vs. cluster randomization, and
present a method using video recordings of visits to assess
contamination, a key potential outcome of our decision
to randomize by patients, rather than clinics or clinicians.
Pursuing adherence as an outcome of decision support
technologies is pertinent for clinical policymaking, but it
is challenging from a clinical trials design standpoint,
especially when few patients take up the medication ofTrials 2009, 10:113 http://www.trialsjournal.com/content/10/1/113
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interest after the consultation. In this case, the power of a
trial to measure differences in this outcome depends not
only on the efficacy of the intervention, but also on the
proportion of patients at risk of nonadherence. The latter
depends on the fraction of patients who leave the consul-
tation with a prescription, a number that could be sub-
stantially smaller than the number randomized. Most
cohort studies of medication use cannot ascertain the
patients who had a discussion about medication use and
left the consultation without a prescription. Conse-
quently, the proportion of patients who will begin a new
medication is often unknown prior to the study. This pilot
study will offer an estimate of the proportion of patients
likely to take on bisphosphonates after the study visit, this
estimate can inform the size of larger trials of this inter-
vention seeking to evaluate the impact of decision aids on
adherence to medication.
An important reason to run feasibility trials of decision
aids designed for use in clinical practice is that these tools
could directly impact the content and duration of the con-
sultation in favorable or unfavorable ways. When clini-
cians at multiple sites with different interests and
priorities see eligible patients, they may not perceive the
need to use the decision aid for this particular decision,
may not find it appropriate for use in some patients, and
may not use the decision aid appropriately [40]. Thus, an
evaluation of the feasibility of the decision aid aided by
video recording of as many visits as possible provides a
rich database to ascertain these challenges. Results may
lead to process modifications in trial design, revised crite-
ria for selection of clinicians and patients, or changes in
the decision aid itself, prior to a larger efficacy study.
These insights will also affect efforts to implement effec-
tive decision aids in practice [41,42].
In conclusion, the OSTEOPOROSIS CHOICE trial is designed
to provide initial empirical evidence of feasibility and effi-
cacy of a novel approach -- decision aids -- to improve
adherence to medication for patients with osteoporosis.
We will also seek to assess the feasibility and effect on
validity of patient-level randomization as an alternative to
cluster randomization at the clinician and clinic level in
preliminary studies of decision aid efficacy. The results
will inform the design of a larger trial that could provide
more precise estimates of the efficacy of the decision aid.
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